<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ALNY</title>
	<atom:link href="http://www.stockbloghub.com/tag/alny/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALNY) Alnylam States Preclinical Data</title>
		<link>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523</link>
		<comments>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523#comments</comments>
		<pubDate>Tue, 03 Jan 2012 19:15:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89523</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington&#8217;s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of the gene responsible for Huntington&#8217;s disease. Further, ALN-HTT was well tolerated in these studies. ALN-HTT is being developed in collaboration with Medtronic, Inc. (MDT) and the CHDI Foundation. Alnylam expects to file an investigational new drug application (IND) application for the candidate in 2012. Approval of the IND by the US Food &#38; Drug Administration (FDA) will allow the candidate to enter early stage clinical trials. Besides ALN-HTT, Alnylam is developing ALN-RSV01 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish</title>
		<link>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197</link>
		<comments>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:05:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88197</guid>
		<description><![CDATA[We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam’s third quarter 2011 loss of 31 cents per share was narrower than the Zacks Consensus Estimate of a loss 36 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. The loss was, however, wider than the year-ago loss of $0.23 per share. Revenues for the reported quarter fell 24.9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898</link>
		<comments>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:19:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87898</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study is being conducted in RSV-infected lung transplant patients at 33 lung transplant centers in six countries. Data from the study is expected in mid-2012. Alnylam is developing ALN-RSV01 on its own while Cubist Pharmaceuticals (CBST) has the opt-in right to collaborate with the company in future for the lung transplant indication. Kyowa Hakko Kirin has opt-in rights for the candidate in Asia. Alnylam’s RNAi technology is potentially revolutionary. Alnylam is utilizing this know-how for selectively turning off the activity of certain genes to build a pipeline of drug candidates to treat a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data</title>
		<link>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547</link>
		<comments>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:32:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87547</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR). Data from the trials showed that ALN-TTR01 led to statistically significant reductions in serum TTR protein levels for the treatment of ATTR. Overall, the candidate has proved to be well tolerated with no serious adverse events observed in the study. We believe the encouraging data further highlights the potential of RNAi as a new class of therapeutics. This is the first time an RNAi has silenced a disease-causing gene in clinical trials. ALN-TTR01 is part of Alnylam’s core product strategy, Alnylam 5&#215;15, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757#comments</comments>
		<pubDate>Thu, 06 Oct 2011 23:38:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84757</guid>
		<description><![CDATA[Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates a situation where the cholesterol levels in the blood are higher than normal. The randomized, single-blind, placebo-controlled, single-ascending dose study intends to evaluate the safety and tolerability of the candidate in patients suffering from high low-density lipoprotein cholesterol (LDLc or “bad” cholesterol). Moreover, the clinical activity of ALN-PCS is also expected to be assessed through the study on the basis of measurements of plasma PCSK9 protein and serum LDLc. Results from the study, which is being conducted in the UK, are expected by year end. ALN-PCS is a part of Alnylam’s core product strategy &#8211; 5&#215;15 introduced ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291</link>
		<comments>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291#comments</comments>
		<pubDate>Thu, 23 Jun 2011 19:34:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77291</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s first quarter loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and also the year-ago loss of 29 cents. Lower revenues and higher research and development expenses led to the greater loss. Revenues for the reported quarter fell 15% from the prior year to $20.9 million but were in line with the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reported Loss Widens</title>
		<link>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669</link>
		<comments>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669#comments</comments>
		<pubDate>Mon, 09 May 2011 21:33:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73669</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents. Revenues came in at $21.1 million, well below the Zacks Consensus Estimate of $26 million. Lower revenues and higher operating expenses led to the wider first quarter 2011 loss. Quarter in Detail Revenues, which include license fees, milestone-related payments and other payments, declined 29.3% from the year-ago period during the first quarter of 2011. Isis Pharma earned a $750,000 milestone payment from OncoGenex (OGXI) on the initiation of a phase II study with OGX-427. First quarter revenues also included revenues recognized under the company’s collaboration agreement with GlaxoSmithKline (GSK). Isis Pharma could receive another ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Signs IP Deal with NYU</title>
		<link>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403</link>
		<comments>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403#comments</comments>
		<pubDate>Mon, 11 Apr 2011 03:01:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70403</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced that it has received an exclusive license from the New York University (NYU) for intellectual property covering therapeutic uses of miR-33a and miR-33b to treat diseases such as atherosclerosis and metabolic syndrome. The license was obtained by Regulus Therapeutics Inc., a joint venture company formed by Alnylam in collaboration with Isis Pharmaceuticals (ISIS). In addition to the latest license, Regulus also owns fundamental patent rights related to miR-33a and miR-33b. Atherosclerosis refers to a condition in which the build-up of fatty substances like cholesterol results in the thickening of artery walls. The build-up results in the formation of atherosclerotic lesions or plaques that can slow down or stop the blood flow, ultimately causing myocardial infarction or stroke. Scientist at Regulus and NYU discovered that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Analyst Retains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654</link>
		<comments>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:27:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70654</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation (Zacks #3 Rank – short-term “Hold” rating) on Isis Pharmaceuticals (ISIS). Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments and royalties. Isis Pharma has partnership agreements with leading pharmaceuticals companies like Genzyme (GENZ) and GlaxoSmithKline (GSK) among others. Isis Pharma also has a collaboration agreement with biotech company, Alnylam Pharmaceuticals (ALNY). Both companies have joined hands to form Regulus Therapeutics, Inc., a company that is focused on microRNA (mRNA) therapeutics. Isis Pharma focuses its research and development efforts primarily on cardiovascular, metabolic and neurodegenerative diseases and cancer while its partners are involved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reports Smaller Third Quarter Loss Than Expected</title>
		<link>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805</link>
		<comments>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805#comments</comments>
		<pubDate>Fri, 26 Nov 2010 04:33:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58805</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc.’s (ALNY) third quarter loss of 23 cents per share was narrower than the Zacks Consensus Estimate of 39 cents but wider than the year-ago loss of 22 cents per share. The wider loss in the third quarter of 2010 was primarily attributable to the higher spend on research and development during the quarter. Revenues for the reported quarter climbed 14% to $27.7 million, above the Zacks Consensus Estimate of $26 million. Revenues were inclusive of $14 million from the company’s alliance with Roche (RHHBY), $5.6 million from Alnylam‘s partnership with Takeda Pharmaceuticals, in addition to $8.1 million of expense reimbursement and amortization revenues from Novartis (NVS), the National Institutes of Health, Cubist Pharmaceuticals Inc. (CBST) and Biogen Idec Inc. (BIIB) among others. Research and development (R&#38;D) costs ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Awards Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978</link>
		<comments>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978#comments</comments>
		<pubDate>Fri, 10 Sep 2010 06:05:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50978</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alnylam Pharmaceuticals (ALNY) with a target price of $15. Alnylam, founded in 2002 and headquartered in Cambridge, Massachusetts, focuses on developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam’s founders pioneered the discovery of RNAi, and the company is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Key programs in the areas of respiratory syncytial virus (RSV), Parkinson’s disease (PD), cystic fibrosis (CF) and spinal cord injury round out the company’s core focus. Alnylam generates revenues from research collaborations, grants and licensing of the RNAi technology outside its core focus area. Alnylam has partnerships with several large pharmaceutical companies, such as Novartis (NVS), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals&#8217; Second Quarter Loss Down on Lower Costs</title>
		<link>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791</link>
		<comments>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791#comments</comments>
		<pubDate>Thu, 05 Aug 2010 17:22:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46791</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc.’s (ALNY) second-quarter net loss of 35 cents per share was 20 cents below the loss per share in the second quarter of 2009. The Zacks Consensus Estimate indicated a loss of 30 cents per share for the reported quarter. The narrower year-over-year loss in the second quarter of 2010 was primarily attributable to the lower spend on research and development during the quarter. Revenues for the reported quarter climbed 8% to $26.6 million slightly above the Zacks Consensus Revenue Estimate of $26 million. Revenues were inclusive of $14 million from the company’s alliance with Roche HLDG LTD(RHHBY), $5.5 million from Alnylam‘s partnership with Takeda Pharmaceuticals, $1.9 million in revenues from license fee from Regulus Therapeutics Inc. pertaining to the partnership with Sanofi-Aventis (SNY), in addition to $5.2 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis and Regulus Therapeutics Join To Develop micro RNA</title>
		<link>http://www.stockbloghub.com/2010/06/25/sny-sanofi-aventis-and-regulus-therapeutics-join-to-develop-micro-rna/41290</link>
		<comments>http://www.stockbloghub.com/2010/06/25/sny-sanofi-aventis-and-regulus-therapeutics-join-to-develop-micro-rna/41290#comments</comments>
		<pubDate>Fri, 25 Jun 2010 17:27:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41290</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) and Regulus Therapeutics Inc. recently joined forces to discover, develop, and commercialize microRNA (micro-RiboNucleic Acid) therapeutics. The initial focus of the alliance will be in the area of fibrosis – a group of diseases that cause scarring inside organs. MicroRNA molecules treat diseases by turning parts of genes on or off. The deal, which could be worth more than $750 million, allows Sanofi-Aventis and Regulus to collaborate on microRNA drug discovery and preclinical development in up to four microRNA targets Incorporatedluding Regulus’ lead fibrosis program targeting microRNA-21. Preclinical studies have suggested that microRNA-21 leads to the improvement of cardiac function in fibrotic impaired mice. Under the terms of the deal, Regulus – a joint venture between Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS) – would receive a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/25/sny-sanofi-aventis-and-regulus-therapeutics-join-to-develop-micro-rna/41290/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reports Smaller Loss Than Expected</title>
		<link>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259</link>
		<comments>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259#comments</comments>
		<pubDate>Fri, 14 May 2010 15:55:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37259</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 10 cents per share in the first quarter, well below the Zacks Consensus Estimate of a net loss of 17 cents. However, the reported quarter’s loss was higher than the year-ago period’s net loss of a cent mainly due to lower revenues and higher operating expenses. Following the adoption of a new required accounting standard, Isis is no longer including Regulus Therapeutics&#8217; financial results. Regulus has been established in collaboration with Alnylam Pharmaceuticals (ALNY). First quarter revenues, which include license fees, milestone-related payments and other payments, declined 5.2% to $29.9 million. Despite recognizing a $6 million milestone payment received from Bristol-Myers Squibb (BMY), revenues declined during the reported quarter as the company finished amortizing the revenue associated with the $50 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Misses Expectations &#8211; Revenues Move Up</title>
		<link>http://www.stockbloghub.com/2010/04/18/cbst-cubist-pharmaceuticals-misses-expectations-revenues-move-up/34108</link>
		<comments>http://www.stockbloghub.com/2010/04/18/cbst-cubist-pharmaceuticals-misses-expectations-revenues-move-up/34108#comments</comments>
		<pubDate>Mon, 19 Apr 2010 02:58:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34108</guid>
		<description><![CDATA[Cubist Pharmaceuticals (CBST) reported earnings per share of 34 cents for the first quarter of 2010 compared to 13 cents in the year-ago period. Last year’s quarter included a $20 million charge related to the upfront payment made under an exclusive agreement to Alnylam Pharmaceuticals (ALNY). The Zacks Consensus Estimate for the quarter was 35 cents. However, after treating stock-based compensation as a regular expense and excluding non-recurring items, EPS for the quarter was 43 cents, higher than 37 cents in the year-ago period. Revenue for the quarter recorded a year over year increase of 19% to $144.1 million. The primary reason for increased revenue was higher sales of Cubicin (daptomycin for injection) in the domestic market &#8211; $135.3 million (year-over-year growth of 20%). Sales in the international market increased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/18/cbst-cubist-pharmaceuticals-misses-expectations-revenues-move-up/34108/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/04/14/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating/33722</link>
		<comments>http://www.stockbloghub.com/2010/04/14/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating/33722#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:12:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33722</guid>
		<description><![CDATA[We maintain our Neutral recommendation on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $18. Alnylam Pharmaceuticals, founded in 2002 and headquartered in Cambridge, Massachusetts, develops novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). The company is utilizing the potentially revolutionary RNA interference technology, natural cellular process for selectively turning off the activity of genes, to build a pipeline of drug candidates to treat a wide array of diseases, such as respiratory syncytial virus, Parkinson’s disease, cystic fibrosis and spinal cord injury. The company is aiming to broaden the scope of its scientific leadership by significantly expanding the range of tissues and cell types targeted by RNAi therapeutics. Alnylam expects to have at least four RNAi therapeutics programs under clinical development by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating/33722/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Earns Gets $20 Million Payment</title>
		<link>http://www.stockbloghub.com/2010/03/27/alny-alnylam-pharmaceuticals-earns-gets-20-million-payment/31691</link>
		<comments>http://www.stockbloghub.com/2010/03/27/alny-alnylam-pharmaceuticals-earns-gets-20-million-payment/31691#comments</comments>
		<pubDate>Sat, 27 Mar 2010 21:05:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31691</guid>
		<description><![CDATA[Recently, Alnylam Pharmaceuticals, Inc. (ALNY) earned $20 million as technology transfer payment from Takeda Pharmaceutical. The amount was paid by Takeda as part of the strategic alliance formed by the companies in 2008. The deal is potentially valued at $1 billion. In May 2008, Alnylam established a five-year strategic platform alliance with Japanese company Takeda Pharmaceuticals Company Ltd. for RNA (ribo nucleic acid) interference (RNAi) therapeutics in the field of oncology and metabolic disease with the right to expand the number of therapeutic fields. RNA interference is a natural cellular process for selectively turning off the activity of genes. By harnessing this natural process, Alnylam is developing novel therapeutics that will utilize the natural RNAi mechanism to selectively suppress genes that produce proteins that play harmful roles in diseases. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/alny-alnylam-pharmaceuticals-earns-gets-20-million-payment/31691/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals&#8217; Loss Widens</title>
		<link>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550</link>
		<comments>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550#comments</comments>
		<pubDate>Wed, 03 Mar 2010 21:53:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29550</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 16 cents per share in the fourth quarter, which was wider than the Zacks Consensus Estimate of a net loss of 11 cents. The company had reported a net loss of 8 cents in the year ago period. The wider-than-expected loss was due to higher operating expenses. For the full year, the company reported a net loss of 31 cents, well above the net loss of 10 cents reported in 2008. Once again, higher operating expenses accounted for the wider loss despite an increase in revenues. Fourth quarter revenues increased 8.8% to $32.3 million. Revenues were boosted by a $10 million sublicensing fee earned by the company in December 2009 from OncoGenex Pharmaceuticals, Inc. (OGXI), which entered into a licensing agreement ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Offers Financial Guidance For 2010</title>
		<link>http://www.stockbloghub.com/2010/01/14/alny-alnylam-pharmaceuticals-offers-financial-guidance-for-2010/24970</link>
		<comments>http://www.stockbloghub.com/2010/01/14/alny-alnylam-pharmaceuticals-offers-financial-guidance-for-2010/24970#comments</comments>
		<pubDate>Thu, 14 Jan 2010 19:18:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24970</guid>
		<description><![CDATA[Alnylam Pharmaceuticals, Inc. (ALNY) recently provided an update on its key pipeline, scientific and business goals for the next 12 to 18 months coupled with financial guidance for 2010. Alnylam, which focuses on developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi), intends to advance ALN-RSV01 to a new mid-stage trial for treating respiratory syncytial virus (RSV). Alnylam expects to start enrolling patients for the study in the first quarter of 2010. ALN-RSV01 is the most advanced pipeline candidate of the company. Alnylam will also advance the development of its other candidates, which are in early-stage or preclinical development. Alnylam expects to have at least four RNAi therapeutics programs under clinical development by the end of 2010. The company is utilizing the potentially ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/alny-alnylam-pharmaceuticals-offers-financial-guidance-for-2010/24970/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2009/11/14/alny-alnylam-pharmaceuticals-posts-wider-loss/20467</link>
		<comments>http://www.stockbloghub.com/2009/11/14/alny-alnylam-pharmaceuticals-posts-wider-loss/20467#comments</comments>
		<pubDate>Sat, 14 Nov 2009 23:36:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20467</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents. The higher loss in the quarter is attributable to higher stock based compensation and legal expenses. Revenues for the quarter came in at $24.2 million as against $25.7 million in the year-ago quarter, down 5.8%. Research and development costs increased 5% to $23.2 million primarily because of increased costs for clinical and pre-clinical programs coupled with increased R&#38;D headcount to support Alnylam’s alliances and development programs. General and administrative expenses increased 56% to $10.7 million. The increase in general and administrative spend was primarily driven by higher professional service fees in association with business activities, primarily legal activities, coupled with increased stock ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/alny-alnylam-pharmaceuticals-posts-wider-loss/20467/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals&#8217; Loss Widens</title>
		<link>http://www.stockbloghub.com/2009/11/12/isis-isis-pharmaceuticals-loss-widens/20383</link>
		<comments>http://www.stockbloghub.com/2009/11/12/isis-isis-pharmaceuticals-loss-widens/20383#comments</comments>
		<pubDate>Thu, 12 Nov 2009 16:16:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20383</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 7 cents per share in the third quarter, which was wider than the Zacks Consensus Estimate of a net loss of 5 cents. The company had reported a net income of 2 cents in the year ago period. The wider-than-expected loss was due to lower revenues and higher operating expenses. Revenues declined 9.1% to $26.8 million. Revenues include license fees, milestone-related payments and other payments. Revenues declined during the reported quarter as the company finished amortizing the revenue associated with the $50 million upfront payment received from Johnson &#38; Johnson’s (JNJ) Ortho-McNeil-Janssen in 2007. The company reported higher expenses during the quarter mainly due to the expansion of its clinical development programs Incorporatedluding additional expenses associated with the phase III clinical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/12/isis-isis-pharmaceuticals-loss-widens/20383/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

